Dr Mark George (Medical University of South Carolina, Distinguished Professor of Psychiatry, Radiology and Neurosciences, Layton McCurdy Endowed Chair), an expert on rTMS for depression treatment stated:
“I think that this is exceedingly good news on a couple of fronts. I think it’s great for patients because it’s always good to have competition, and more people making TMS devices should help more patients get access to the therapy. It’s also historically nice because Magstim launched the first modern uses of TMS that were pioneered in Sheffield and has been around 25 years - so it’s great that they are now present in the clinical arena. This is an excellent progression for clinicians and patients alike”.
Linda Carpenter, MD, (Chief of Butler Hospital’s Mood Disorders Program and recognized expert in major depression and anxiety disorders at, Brown University, Department of Psychiatry, Providence, Rhode Island) said:
"It is wonderful to learn that Magstim now joins two other companies with FDA-cleared TMS devices for treating major depression. More access to TMS therapy will translate to improved quality of life for millions who suffer with a disabling and sometimes lethal brain disorder."
Dr Alvaro Pascual Leone (Professor of Neurology, Harvard Medical School), a leader in the field of TMS, also commented:
"The FDA clearance of the Magstim Rapid2 device for treatment of medication refractory depression is wonderful news for the field of noninvasive brain stimulation and particularly for patients with medication resistant depression. This approval makes more devices available for treatment of patients who stand to benefit from TMS and for whom other treatment options are limited".